The brokerage believes earnings growth beyond FY21 would remain challenging given limited growth drivers and doubling of R&D.

The analyst suggested a stoploss at Rs 447.

Buy Aurobindo Pharma Ltd. at a price target of Rs 750.0 and a stoploss at Rs 725 from entry point.

Buy Aurobindo Pharma Ltd. at a price target of Rs 630.0 and a stop loss at Rs 610 from the entry point.

Sell Aurobindo Pharma Ltd. at a price target of Rs 568.0 and a stop loss at Rs 585 from entry point.

Buy Aurobindo Pharma Ltd. at a price target of Rs 610.0 and a stop loss at Rs 574 from entry point.

Buy Aurobindo Pharma Ltd. at a price target of Rs 722.0 and a stoploss at Rs 668 from entry point.

Buy Aurobindo Pharma at a price target of Rs 850 and a stop loss at Rs 750 from the entry point.

Buy Aurobindo Pharma at a price target of Rs 785 and a stop loss at Rs 732 from entry point.

The scheme was designed on the lines of traffic wardens, a voluntary service where citizens can help the city traffic police regulate vehic...

You might soon be able to buy long-term health savings schemes from health insurance companies. Similarly, you could also get access to com...

You might soon be able to buy long-term health savings schemes and get access to comprehensive health policies from health insurance compan...

Epson said it expects to double its revenues in the next 3 years to about Rs 1,400 cr on the back of growth in categories like printers and...

The newly launched M-series range of monochrome inkjet printers are for corporates who primarily print black and white documents.

General insurance cos, led by New India Assurance and ICICI Lombard, will lobby with Chidambaram to free up third-party motor insurance pre...

Global Investment House has picked up an 11.11% equity stake in MAPE Advisory Group, a boutique investment bank, for about $10 million, val...

The BJP bagged 11 of the 14 seats for which results were declared on course to become the single largest party in the Karnataka assembly.